Arcellx, Inc.
ACLX
Classifica tra le azioni
#2790
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Prezzo delle azioni
$115.07
Ultima sincronizzazione: 2026-05-15
Capitalizzazione di mercato
$6.73B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
34.40%
Paese
US
Scambia Arcellx, Inc. (ACLX)
Categoria
Healthcare
Ricavi di Arcellx, Inc. (ACLX)
Ricavi nel Dec 2025 TTM: $22.29M
Secondo gli ultimi rapporti finanziari di Arcellx, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $22.29M. Nel 2023, l'azienda ha registrato ricavi di $110.32M un aumento rispetto a i ricavi dell'anno 2022, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Arcellx, Inc. da 2018 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $22.29M | -79.35% |
| 2024 | $107.94M | -2.16% |
| 2023 | $110.32M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 56,546.77% |
US
|
|
| $2.23B | 9,897.31% |
US
|
|
| $15.74B | 70,546.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 26,918.25% |
NL
|
